Pleckstrin-2 as a Prognostic Factor and Mediator of Gastric Cancer Progression.
Journal
Gastroenterology research and practice
ISSN: 1687-6121
Titre abrégé: Gastroenterol Res Pract
Pays: Egypt
ID NLM: 101475557
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
01
2021
accepted:
06
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Pleckstrin-2 (PLEK2) is a crucial mediator of cytoskeletal reorganization. However, the potential roles of PLEK2 in gastric cancer are still unknown. PLEK2 expression in gastric cancer was examined by western blotting and real-time PCR. Survival analysis was utilized to test the clinical impacts of the levels of PLEK2 in gastric cancer patients. In vitro and in vivo studies were used to estimate the potential roles played by PLEK2 in modulating gastric cancer proliferation, self-renewal, and tumourigenicity. Bioinformatics approaches were used to monitor the effect of PLEK2 on epithelial-mesenchymal transition (EMT) signalling pathways. PLEK2 expression was significantly upregulated in gastric cancer as compared with nontumour samples. Kaplan-Meier plotter analysis revealed that gastric cancer patients with higher PLEK2 levels had substantially poorer overall survival compared with gastric cancer patients with lower PLEK2 levels. The upregulation or downregulation of PLEK2 in gastric cancer cell lines effectively enhanced or inhibited cell proliferation and proinvasive behaviour, respectively. Additionally, we also found that PLEK2 enhanced EMT through downregulating E-cadherin expression and upregulating Vimentin expression. Our findings demonstrated that PLEK2 plays a potential role in gastric cancer and may be a novel therapeutic target for gastric cancer.
Identifiants
pubmed: 34394345
doi: 10.1155/2021/5527387
pmc: PMC8360755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5527387Informations de copyright
Copyright © 2021 Jun Wang et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interests.
Références
Commun Biol. 2021 May 3;4(1):517
pubmed: 33941818
Nature. 1993 May 27;363(6427):309-10
pubmed: 8497315
J Biol Chem. 1999 Jul 30;274(31):21515-8
pubmed: 10419454
Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):759-63
pubmed: 22335908
J Clin Oncol. 2006 Jun 20;24(18):2903-9
pubmed: 16782930
J Cell Physiol. 2019 Feb;234(2):1416-1425
pubmed: 30078189
Blood. 2007 Feb 1;109(3):1147-55
pubmed: 17008542
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2010 Mar 4;362(9):858-9
pubmed: 20200397
Int J Med Sci. 2020 Jul 25;17(14):2063-2076
pubmed: 32922167
Mol Biol Rep. 2005 Mar;32(1):35-40
pubmed: 15865208
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cell. 1993 May 21;73(4):629-30
pubmed: 8500161
Trends Pharmacol Sci. 2000 Jul;21(7):238-41
pubmed: 10871889
Nature. 1994 Sep 8;371(6493):168-70
pubmed: 8072546
Haematologica. 2014 Jul;99(7):1157-67
pubmed: 24747950
J Cell Biol. 1997 Mar 10;136(5):1071-9
pubmed: 9060471
Biochem Soc Trans. 2001 Aug;29(Pt 4):377-84
pubmed: 11497993
Int J Cancer. 2020 May 1;146(9):2563-2575
pubmed: 31498891
PLoS One. 2011;6(6):e20971
pubmed: 21698244
Biochem Biophys Res Commun. 2007 Sep 21;361(2):270-5
pubmed: 17658464
Biochem J. 2000 Oct 1;351(Pt 1):19-31
pubmed: 11001876
Cell Signal. 2021 Aug;84:110025
pubmed: 33915247
J Clin Invest. 2018 Jan 2;128(1):125-140
pubmed: 29202466
Gene. 2016 Dec 5;594(1):23-29
pubmed: 27581786
Clin Cancer Res. 2017 Mar 15;23(6):1586-1597
pubmed: 27620279
J Biol Chem. 1995 Oct 6;270(40):23317-21
pubmed: 7559487
J Exp Clin Cancer Res. 2019 Jun 10;38(1):247
pubmed: 31182136